ArticleCureus2024
Persistent Lupus Anticoagulant Positivity and Long-Term Sequelae Following Mild COVID-19.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pharmacological and non-pharmacological management of long COVID.Virology journal · 2026Review
- Prevalence and Cardiopulmonary Characteristics of Post-COVID Syndrome at a Hungarian Tertiary Referral Hospital.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a case of persistent lupus anticoagulant (LAC) positivity following mild COVID-19 in a 64-year-old Japanese male with a history of atrial fibrillation. The patient experienced post-COVID-19 condition symptoms, including intermittent fatigue, taste disturbance, and persistent numbness in the upper arm, persistently for over 10 months. Laboratory investigations revealed prolonged activated partial thromboplastin time (aPTT) of 70.0 seconds, positive LAC of 1.5, and positive anti-cardiolipin-beta2-glycoprotein I complex antibody of 4.3 U/mL. This case highlights the potential for long-term LAC positivity after mild COVID-19 and raises questions about its association with post-COVID-19 conditions. The persistence of LAC positivity is noteworthy, as previous studies suggest that virus-induced LAC typically resolves within two to three months. Further research is needed to elucidate the long-term dynamics of LAC in post-COVID-19 condition patients and its clinical implications, particularly in relation to thrombotic complications associated with COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.